Role of substance P in the cardiovascular system.
Autor: | Mistrova E; Department of Physiology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic., Kruzliak P; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Comenius University, Bratislava, Slovak Republic; 2(nd) Department of Internal Medicine, Faculty of Medicine, Masaryk University, Brno, Czech Republic. Electronic address: kruzliakpeter@gmail.com., Chottova Dvorakova M; Department of Physiology, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic; Biomedical Center, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. |
---|---|
Jazyk: | angličtina |
Zdroj: | Neuropeptides [Neuropeptides] 2016 Aug; Vol. 58, pp. 41-51. Date of Electronic Publication: 2015 Dec 08. |
DOI: | 10.1016/j.npep.2015.12.005 |
Abstrakt: | This article provides an overview of the structure and function of substance P signalling system and its involvement in the cardiovascular regulation. Substance P is an undecapeptide originating from TAC1 gen and belonging to the tachykinin family. The biological actions of substance P are mainly mediated through neurokinin receptor 1 since substance P is the ligand with the highest affinity to neurokinin receptor 1. Substance P is widely distributed within the central and peripheral nervous systems as well as in the cardiovascular system. Substance P is involved in the regulation of heart frequency, blood pressure and in the stretching of vessels. Substance P plays an important role in ischemia and reperfusion and cardiovascular response to stress. Additionally, it has been also implicated in angiogenesis, pain transmission and inflammation. The substance P/neurokinin receptor 1 receptor system is involved in the molecular bases of many human pathological processes. Antagonists of neurokinin receptor 1 receptor could provide clinical solutions for a variety of diseases. Neurokinin receptor 1 antagonists are already used in the prevention of chemotherapy induced nausea and vomiting. (Copyright © 2015 Elsevier Ltd. All rights reserved.) |
Databáze: | MEDLINE |
Externí odkaz: |